N. Arvind Dasari, MD, MS

Articles

DPD Testing and Medication Dosage Adjustments in mCRC Patients

June 16th 2025

Panelists discuss how dihydropyrimidine dehydrogenase testing remains controversial with institutions debating whether to implement universal pharmacogenomic testing given the challenges of standardization, genotype-phenotype correlation, and low incidence of severe deficiency.

The Importance of Biomarker Testing in mCRC

June 16th 2025

John L. Marshall, MD; Marwan G. Fakih, MD; Arvind N. Dasari, MD, MS; and Katrina S. Pedersen, MD, discuss how precision medicine has transformed metastatic colorectal cancer treatment through comprehensive molecular testing, targeted therapies like BRAF/EGFR inhibition and immunotherapy combinations for microsatellite instability-high tumors, and personalized approaches to treatment sequencing and dosing modifications that balance efficacy with quality of life considerations.

FRESCO-2: A Global Phase 3 Multiregional Clinical Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients With Refractory Metastatic Colorectal Cancer

August 29th 2023

Arvind Dasari, MD, MS, presents data from the FRESCO-2 clinical trial evaluating fruquintinib in patients with refractory metastatic colorectal cancer, and provides insights on the clinical implications of the results.

Dr. Dasari on the Investigation of Fruquintinib in mCRC

October 6th 2022

Nageshwara Arvind Dasari, MD, discusses the patient population observed in the phase 3 FRESCO-2 trial in metastatic colorectal cancer.

Rapid Readout: ctDNA Dynamics and Clinical Outcomes in the Adjuvant Management of Colorectal Cancer (GALAXY Study)

February 18th 2022

Insight on the observational GALAXY study, which analyzed the relationship between circulating tumor DNA and clinical outcomes in the adjuvant management of colorectal cancer.

Dr. Dasari on Eligibility Criteria for the FRESCO-2 trial With Fruquintinib in CRC

April 5th 2021

Nageshwara Arvind Dasari, MD, discusses the eligibility criteria for the phase 3 FRESCO-2 trial, which examined the use of fruquintinib in patients with metastatic colorectal cancer.

Dr. Dasari on the Rationale for the FRESCO-2 Trial With Fruquintinib in mCRC

February 19th 2021

Nageshwara Arvind Dasari, MD, discusses the rationale to evaluate fruquintinib in the ongoing, phase 3 FRESCO-2 trial in patients with metastatic colorectal cancer.

Dr. Dasari on the Potential Clinical Implications of Fruquintinib in mCRC

January 25th 2021

Nageshwara Arvind Dasari, MD, discusses the potential clinical implications with fruquintinib in metastatic colorectal cancer.

x